Anti-Cytokeratin 7 Antibody, clone RCK105

Description

• General description: Keratin, type II cytoskeletal 7 (UniProt: P08729; also known as Cytokeratin-7, CK-7, Keratin-7, K7, Sarcolectin, Type-II keratin Kb7) is encoded by the KRT7 (also known as SCL) gene (Gene ID: 3855) in human. Cytokeratins are the intermediate filament proteins of epithelia that display high degree of molecular diversity. They are heteropolymeric filaments formed by pairing of type I and type II keratins that are expressed in a highly specific patterns depending on the epithelial type and stage of cellular differentiation. They contain a central rod domain of about 310 amino acids with α-helical conformation bordered by non-helical head and tail domains of variable length. The head domain consists of subdomains V1 and H1. The central a-helical rod domain is composed of subdomains 1A, 1B, 2A, and 2B connected by the linkers L1, L12, and L2. The tail domain then consists of subdomains H2 and V2. They provide stability between epithelial cells and their attachment to basement membrane. Keratins also serve as tumor markers and epithelial differentiation markers. Multiple human epithelial keratins have been resolved with 2D-gels electrophoresis. These can be divided into acidic (pI <5.7) and basic (pI >6.0) subfamilies. The acidic keratins have molecular weights that range from 40 to 55 kDa. The basic keratins have molecular weights that range from 56 to 70 kDa. Members of the acidic and basic subfamilies are reported to be present in pairs. The composition of keratin pairs varies with the epithelial cell type, stage of differentiation, cellular growth environment, and the disease state. Keratin 7 is expressed in cultured epidermal, bronchial, and mesothelial cells. It is observed throughout the glandular cells in the junction between stomach and esophagus but is absent in esophagus. Its expression is also observed in a variety of carcinomas and in tumor cells of mammary and extramammary Paget disease. Keratin-7 expression can be used to distinguish ovarian and gastrointestinal carcinomas. (Ref.: Chu, P., et al. (2000). Modern Pathol. 13(9); 962-972; Kaba, A., et al. (1999). Biochimie. 81(7); 709-715).
• Specificity: MAB3226 reacts with a subgroup of glandular epithelial and their tumors, as well as transitional epithelium and transitional carcinoma. It reacts with a 58 kDa protein corresponding to cytokeratin 7.
• Immunogen: Cytokeratins from the human bladder carcinoma cell line T24.
• Application: Anti-Cytokeratin 7 Antibody, clone RCK105 is an antibody against Cytokeratin 7 for use in FC, WB, IC, IH.
• Linkage: Replaces: MABT150
• Physical form: Format: Purified
• Storage and Stability: Maintain at -20°C in undiluted aliquots up to 6 months. Avoid repeated freeze/thaw cycles.
• Other Notes: Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
• Legal Information: CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
• Disclaimer: Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.